Efficacy of high-dose methylprednisolone in patients with Crimean-Congo haemorrhagic fever and severe thrombocytopenia
- 1 April 2013
- journal article
- research article
- Published by SAGE Publications in Tropical Doctor
- Vol. 43 (2) , 49-53
Abstract
Crimean-Congo haemorrhagic fever (CCHF) is an acute viral haemorrhagic disease that is now endemic in south eastern Iran. The most important factor associated with mortality is a platelet count of less than 50,000/mL. The purpose of this study is to compare treated cases with severe thrombocytopenia using ribavirin with high-dose methylprednisolone (HDMP) with patients receiving ribavirin without HDMP. A clinical trial was conducted for confirmed patients with CCHF and severe thrombocytopenia (platelet count less than 50,000/mL) admitted to Boo-Ali Hospital in Zahedan between January 2010 and October 2011. The intervention group was given oral ribavirin, supportive managements and HDMP and the controls were treated with ribavirin and supportive management. Following HDMP therapy in hospitalized patients with severe thrombocytopenia, the platelet count increased within 36 h and the leukocyte count within 48 h of the beginning of treatment. Fewer in the intervention group required a transfusion of blood products than in the controls (P < 0.001). No one in the intervention group died. It seems that high-dose methylprednisolone is effective in the treatment of patients with CCHF. The increased platelet count and reduction of blood product requirement for severe CCHF patients after receiving HDMP are promising results. Further investigation is necessary in order to determine the efficacy of corticosteroid and its effect on outcome.Keywords
This publication has 14 references indexed in Scilit:
- Interacting Roles of Immune Mechanisms and Viral Load in the Pathogenesis of Crimean-Congo Hemorrhagic FeverClinical and Vaccine Immunology, 2010
- High-dose methylprednisolone in children with Crimean-Congo haemorrhagic feverTropical Doctor, 2010
- Interferon and cytokine responses to Crimean Congo hemorrhagic fever virus; an emerging and neglected viral zonoosisCytokine & Growth Factor Reviews, 2008
- Clinical and Epidemiologic Features of Crimean-Congo Hemorrhagic Fever Among Children and Adolescents From Southeastern IranThe Pediatric Infectious Disease Journal, 2008
- Genetic Variation in Iranian Mints on the Bases of RAPD AnalysisPakistan Journal of Biological Sciences, 2006
- Crimean-Congo hemorrhagic fever in Southeast of IranJournal of Infection, 2006
- Crimean–Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapyJournal of Infection, 2006
- Clinical Outcomes in Crimean-Congo Hemorrhagic Fever: A Five-years Experience in the Treatment of Patients in Oral RibavirinInternational Journal of Virology, 2005
- Characteristics of Patients with Crimean-Congo Hemorrhagic Fever in a Recent Outbreak in Turkey and Impact of Oral Ribavirin TherapyClinical Infectious Diseases, 2004
- The Efficacy of Oral Ribavirin in the Treatment of Crimean-Congo Hemorrhagic Fever in IranClinical Infectious Diseases, 2003